Coronavirus update: Pfizer/BioNTech press for emergency vaccine use as WHO hits Gilead’s remdesivir

Advertisement

BEGIN ARTICLE PREVIEW:

The U.S. has moved one step closer to getting its first COVID-19 vaccine, with BioNTech (BNTX) — Pfizer’s (PFE) development partner — filing for emergency use authorization Friday morning.“Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Pfizer CEO Albert Bourla.With the coronavirus crisis reaching a crescendo worldwide, steps toward approving and distributing a COVID-19 inoculation have taken on increasing urgency.BioNTech’s move comes just days after the two companies announced their two-dose vaccine is 95% effective against the coronavirus, and that they planned to file for regulatory approval “within days.”While data supporting the statement has yet to be released, health officials are cautiously optimistic. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said a vaccine’s efficacy is one thing — but the effectiveness in the real world is another.“If you like at highly efficacious vaccines through the years, they’ve crushed formidable outbreaks like smallpox, like polio, like measles,” Fauci said — calling the 95% threshold “ …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE